JP7296321B2 - 神経変性障害または脳卒中の治療に用いる遺伝子構築物 - Google Patents
神経変性障害または脳卒中の治療に用いる遺伝子構築物 Download PDFInfo
- Publication number
- JP7296321B2 JP7296321B2 JP2019554630A JP2019554630A JP7296321B2 JP 7296321 B2 JP7296321 B2 JP 7296321B2 JP 2019554630 A JP2019554630 A JP 2019554630A JP 2019554630 A JP2019554630 A JP 2019554630A JP 7296321 B2 JP7296321 B2 JP 7296321B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- disease
- composition
- bdnf
- trkb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1705484.2A GB201705484D0 (en) | 2017-04-05 | 2017-04-05 | Genetic construct |
| GB1705484.2 | 2017-04-05 | ||
| PCT/GB2018/050824 WO2018185468A1 (en) | 2017-04-05 | 2018-03-28 | Genetic construct for use in the treatment of neurodegenerative disorder or stroke |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020516244A JP2020516244A (ja) | 2020-06-11 |
| JP2020516244A5 JP2020516244A5 (cg-RX-API-DMAC7.html) | 2021-05-06 |
| JP7296321B2 true JP7296321B2 (ja) | 2023-06-22 |
Family
ID=58682577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554630A Active JP7296321B2 (ja) | 2017-04-05 | 2018-03-28 | 神経変性障害または脳卒中の治療に用いる遺伝子構築物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200046850A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3606546B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7296321B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102616629B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110809476B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018248651B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3058549A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2881176T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201705484D0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019012000A (cg-RX-API-DMAC7.html) |
| PL (1) | PL3606546T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3606546T (cg-RX-API-DMAC7.html) |
| RU (1) | RU2757932C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018185468A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200057051A (ko) * | 2017-09-27 | 2020-05-25 | 시질론 테라퓨틱스, 인크. | 활성 세포를 포함하는 방법, 조성물 및 이식 가능한 요소 |
| JP2022514863A (ja) * | 2018-12-19 | 2022-02-16 | ヴェルサメブ アーゲー | タンパク質をコードするrna |
| WO2020179844A1 (ja) | 2019-03-04 | 2020-09-10 | 公益財団法人東京都医学総合研究所 | Trk断片をコードする核酸構築物、及びその利用 |
| US12649930B2 (en) | 2019-03-27 | 2026-06-09 | Sigilon Therapeutics, Inc. | Compositions, devices, and methods for treating Fabry disease |
| GB202004832D0 (en) * | 2020-04-01 | 2020-05-13 | Instituto De Medicina Molecular Faculdade De Medicina Univ De Lisboa | Therapeutic agaents, pharmaceutical compositions, and associated biomarkers |
| EP4262846A4 (en) * | 2020-12-18 | 2024-11-20 | Baylor College of Medicine | ADMINISTRATION OF ABETA VARIANTS FOR INHIBITION OF AGGREGATION |
| CN114933657B (zh) * | 2021-08-25 | 2024-02-02 | 上海交通大学医学院 | 神经生长因子突变体重组蛋白及其应用 |
| CN118256562A (zh) * | 2022-12-26 | 2024-06-28 | 科辉智药(深圳)新药研究中心有限公司 | 一种用于中枢神经系统疾病治疗的基因序列构建体及其应用 |
| KR20250142340A (ko) | 2023-02-02 | 2025-09-30 | 퀘세라 리미티드 | 재조합 아데노-부속 바이러스 벡터 |
| EP4413993A1 (en) * | 2023-02-10 | 2024-08-14 | Dompe' Farmaceutici S.P.A. | Method of obtaining recombinant human brain-derived neurotrophic factor |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030124095A1 (en) | 2001-12-31 | 2003-07-03 | Regents Of The University Of California | Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex |
| WO2009120978A2 (en) | 2008-03-27 | 2009-10-01 | The Ohio State University | Treatment of metabolic-related disorders using hypothalamic gene transfer of bdnf and compositions therfor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2588221C (en) * | 1999-06-08 | 2013-07-09 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| EP3165537A1 (en) * | 2008-12-19 | 2017-05-10 | H. Lundbeck A/S | Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders |
| ES2694592T3 (es) * | 2012-03-15 | 2018-12-21 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF |
| GB2547179A (en) | 2015-10-26 | 2017-08-16 | Quethera Ltd | Genetic construct |
-
2017
- 2017-04-05 GB GBGB1705484.2A patent/GB201705484D0/en not_active Ceased
-
2018
- 2018-03-28 MX MX2019012000A patent/MX2019012000A/es unknown
- 2018-03-28 PT PT187159116T patent/PT3606546T/pt unknown
- 2018-03-28 EP EP18715911.6A patent/EP3606546B1/en active Active
- 2018-03-28 CN CN201880023931.XA patent/CN110809476B/zh active Active
- 2018-03-28 JP JP2019554630A patent/JP7296321B2/ja active Active
- 2018-03-28 PL PL18715911T patent/PL3606546T3/pl unknown
- 2018-03-28 ES ES18715911T patent/ES2881176T3/es active Active
- 2018-03-28 CA CA3058549A patent/CA3058549A1/en active Pending
- 2018-03-28 US US16/497,412 patent/US20200046850A1/en not_active Abandoned
- 2018-03-28 WO PCT/GB2018/050824 patent/WO2018185468A1/en not_active Ceased
- 2018-03-28 RU RU2019131098A patent/RU2757932C2/ru active
- 2018-03-28 AU AU2018248651A patent/AU2018248651B2/en active Active
- 2018-03-28 KR KR1020197032606A patent/KR102616629B1/ko active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030124095A1 (en) | 2001-12-31 | 2003-07-03 | Regents Of The University Of California | Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex |
| WO2009120978A2 (en) | 2008-03-27 | 2009-10-01 | The Ohio State University | Treatment of metabolic-related disorders using hypothalamic gene transfer of bdnf and compositions therfor |
Non-Patent Citations (2)
| Title |
|---|
| Investigative Ophthalmology & Visual Science, 2003, Vol.44, NO.10, pp.4357-4365 |
| The Journal of Neuroscience, Vol.22, No.10, pp.3977-3986 |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019131098A (ru) | 2021-05-05 |
| US20200046850A1 (en) | 2020-02-13 |
| AU2018248651B2 (en) | 2024-07-25 |
| MX2019012000A (es) | 2020-01-27 |
| RU2757932C2 (ru) | 2021-10-25 |
| GB201705484D0 (en) | 2017-05-17 |
| CN110809476A (zh) | 2020-02-18 |
| JP2020516244A (ja) | 2020-06-11 |
| PL3606546T3 (pl) | 2021-11-08 |
| KR102616629B1 (ko) | 2023-12-21 |
| CA3058549A1 (en) | 2018-10-11 |
| EP3606546B1 (en) | 2021-04-28 |
| RU2019131098A3 (cg-RX-API-DMAC7.html) | 2021-07-27 |
| WO2018185468A1 (en) | 2018-10-11 |
| KR20200005549A (ko) | 2020-01-15 |
| EP3606546A1 (en) | 2020-02-12 |
| CN110809476B (zh) | 2024-02-27 |
| AU2018248651A1 (en) | 2019-10-17 |
| ES2881176T3 (es) | 2021-11-29 |
| PT3606546T (pt) | 2021-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3606546B1 (en) | Genetic construct for use in the treatment of neurodegenerative disorder or stroke | |
| JP7503590B2 (ja) | 遺伝子構築物 | |
| Pernet et al. | The role of Nogo-A in axonal plasticity, regrowth and repair | |
| EP3074034B1 (en) | Treatment of inflammatory disease using caveolin linked to an internalisation peptide | |
| JP2018525337A (ja) | 軽度認知障害の処置のためのjnkシグナル伝達経路の細胞透過性ペプチド阻害剤の新規使用 | |
| EP4384202A1 (en) | Suppression of neurodegeneration with zinc transporter protein 7 | |
| US20180170983A1 (en) | New Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Mild Cognitive Impairment | |
| KR20210116559A (ko) | 중추신경계 질환의 치료 방법 | |
| Matsuoka | Humanin; a defender against Alzheimer's disease? | |
| KR102772298B1 (ko) | 미엘린 장애의 치료를 위한 조성물 및 방법 | |
| CA3001036C (en) | Recombinant vectors encoding tyrosine kinase receptor b and agonists thereof | |
| HK1252168B (en) | Genetic construct | |
| Tracy | A novel postsynaptic location for Kv7 channels and their role in memory and nanoparticle advancement for dementia therapeutics | |
| EP4735592A2 (en) | Therapeutic method for modulating compartmented cyclic adenosine monophosphate in reactive astrocytes | |
| Joshi | Engineering Fusion Intrabodies as Potential Parkinson's Disease Therapeutics | |
| HK1229701A1 (en) | Treatment of inflammatory disease using caveolin linked to an internalisation peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20191127 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210325 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210325 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220308 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220531 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220908 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230306 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230606 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230612 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7296321 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |